FDA Clears Zyn to Be Advertised as Less Harmful Than Cigarettes

The federal government has, for the first time, allowed a nicotine pouch to tell smokers it is the safer choice — within strict limits.

What the FDA did

The Food and Drug Administration granted Zyn a "modified risk tobacco product" order, allowing its maker — Swedish Match USA, a subsidiary of Philip Morris International — to market the pouches with the claim that switching completely from cigarettes to Zyn reduces exposure to harmful chemicals and the risk of diseases such as lung and mouth cancer, heart disease and stroke, The Hill reported. It is the first time any nicotine pouch has received the designation. The FDA was emphatic that the order is not a clean bill of health: it stressed that no tobacco product is safe, that Zyn still delivers highly addictive nicotine, and that the products are intended only for adults who already smoke — not for young people or non-users. The authorization can be revoked if the company markets the pouches in ways that could appeal to minors.

The harm-reduction case

The decision builds on a 2025 order that first cleared Zyn for sale, according to the FDA. Supporters of the harm-reduction approach note that pouches contain nicotine but not tobacco leaf, and none of the thousands of combustion byproducts produced when a cigarette burns — a far smaller toxic load than smoking. Company data submitted to the agency reported that a meaningful share of smokers who tried Zyn switched away from cigarettes; Philip Morris cast the order as validation of smoke-free alternatives, CNBC reported. Those switching figures come from the manufacturer's own submissions, not independent studies.

The critics

Opponents — including the American Lung Association and university tobacco researchers — argue the evidence is too thin and the risk of widening nicotine addiction too great. They note that Zyn was not widely available in the U.S. until 2019, so there is no long-term domestic data on disease outcomes, and that nicotine itself carries cardiovascular risk regardless of how it is delivered. Their central worry is youth uptake: the 2024 National Youth Tobacco Survey found about 1.8 percent of middle and high school students — roughly 480,000 young people — reported using nicotine pouches, and critics contend that flavors and discreet, scentless designs, amplified by social-media promotion, risk drawing in users who never smoked.

The unresolved question

The order lets Zyn make specific disease-risk comparisons to cigarettes in advertising aimed at adult smokers; it does not permit claims that the product is safe, that it helps people quit nicotine entirely, or that non-smokers should try it. Whether the designation mainly helps smokers move away from a deadlier habit or mainly normalizes nicotine for a new generation is the question public-health officials and researchers will now watch — and it is unlikely to be settled soon.